Abstract 702: Chinese Medicine formulation LQ inhibits FUCCI-expressing HeLa cells at the G0/G1 phase in 2D and 3D culture and invasion with Gelfoam® 3D culture.

Abstract

Abstract Traditional Chinese Medicine formula LQ has previously demonstrated anti-tumor and anti-metastasis efficacy. Here, we used fluorescence ubiquitination-based cell cycle indicator (FUCCI) to monitor cell cycle arrest after LQ treatment. FUCCI-HeLa cells were cultured in two dimensional (2D) monolayer, 3D Matrigel®, and 3D Gelform®. Changes of cell cycle status after 24 hours LQ treatment (90mg/ml) were observed using the Olympus FV1000 confocal imaging system. Paclitaxel (Taxol) was used as the positive control which induced a G2/M block of cell cycle. LQ blocked FUCCI-HeLa cells in the G0/G1 phase of the cell cycle in all cultures. In monolayer culture, the control had approximately 45% of the cells in G2/M phase. In contrast, the LQ-treated cells were mostly in the G0/G1 phase (>90%). In 3D dimensional culture (Matrigel®), cancer cells formed spheres. The colonies in control group had 40% of the cells in G2/M phase, but only 15% in LQ-treated culture. The cancer cells at the surface of the sphere were mostly in G2/M phase, and the cancer cells in the center of colonies were in G0/G1 phase. In 3D Gelform® culture, cells grew along the structures of the Gelform®. The control culture had approximately 45% of cells in G2/M phase. In contrast, the cells in LQ-treated culture were mostly in G0/G1 phase (>80%). The cells in control group migrated to 250∼300 μm deep in the Gelfoam®, but only 150∼200 μm deep in LQ-treated culture. FUCCI-HeLa cells in different culture systems demonstrated the efficacy of LQ on the cell cycle and migration. Citation Format: Lei Zhang, Chengyu Wu, Shuya Yano, Robert M. Hoffman. Chinese Medicine formulation LQ inhibits FUCCI-expressing HeLa cells at the G0/G1 phase in 2D and 3D culture and invasion with Gelfoam® 3D culture. [abstract]. In: Proceedings of the 104th Annual Meeting of the American Association for Cancer Research; 2013 Apr 6-10; Washington, DC. Philadelphia (PA): AACR; Cancer Res 2013;73(8 Suppl):Abstract nr 702. doi:10.1158/1538-7445.AM2013-702